According to IQVIA, sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution achieved annual ...

Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting earnings tomorrow morning. Here’s what ...

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution.

Glenmark Pharmaceuticals launches a generic ophthalmic solution for glaucoma in the US market, adding to its growing ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin ...

According to IQVIA sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million.

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of clindamycin phosphate foam, 1%. Glenmark’s clindamycin phosphate foam, 1% is bioequivalent and therapeutically equivalent to the ...

Glenmark Pharmaceuticals Ltd's US division has introduced a generic version of Clindamycin Phosphate foam, an acne treatment. This product is equivalent to Mylan's Evoclin foam and joins a market with ...

Glenmark Pharmaceuticals's US arm has launched a generic version of Clindamycin Phosphate foam, an antibiotic acne treatment.

Zydus Lifesciences has signed an exclusive agreement with Synthon for the development and commercialisation of a novel ...

With the rising incidence of cancer in India, AstraZeneca India's breast cancer medicine trastuzumab deruxtecan (sold under ...